27688-86-4

Basic information

• Product Name: 3,4-bis(benzyloxy)phenol
• Synonyms: 3,4-bis(benzyloxy)phenol
• CAS NO: 27688-86-4
• Molecular Formula: C₂₀H₁₈O₃
• Molecular Weight: 306.35512
• Mol File: 27688-86-4.mol
• Article Data: 21

Chemical Properties

• Melting Point: 110.5-111.5 °C(Solv: benzene (71-43-2))
• Boiling Point: 490.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.190±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.95±0.20(Predicted)
• CAS DataBase Reference: 3,4-bis(benzyloxy)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-bis(benzyloxy)phenol(27688-86-4)
• EPA Substance Registry System: 3,4-bis(benzyloxy)phenol(27688-86-4)

Safety Data

• Hazardous Substances Data: 27688-86-4(Hazardous Substances Data)

Upstream product

• 5447-02-9 3,4-dibenzyloxybenzaldehyde 
• 120951-85-1 1,2-di-O-benzyl-4-O-tert-butyldimethylsilylbenzenetriol 
• 100-39-0 benzyl bromide 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 100-44-7 benzyl chloride 
• 121-33-5 vanillin 

Downstream Products

• 88755-15-1 1,2-dibenzyloxy-4-methoxybenzene 
• 136944-34-8 trans-β-(3,4-Dibenzyloxyphenoxy)acrylic Acid 
• 27688-92-2 1-(3,4-bis(benzyloxy)phenoxy)-3-(isopropylamino)-2-propanol 
• 62312-68-9 1-(3,4-Bis-benzyloxy-phenoxy)-3-tert-butylamino-propan-2-ol 
• 157259-31-9 4,5-dibenzyloxy-2-dimethylaminomethylphenol 
• 120951-85-1 1,2-di-O-benzyl-4-O-tert-butyldimethylsilylbenzenetriol 
• 177704-09-5 (2S)-(+)-1-(3',4'-dibenzyloxyphenoxy)-2,3-epoxypropane 
• 27688-87-5 (S)-3-(3,4-dibenzyloxyphenoxy)-1,2-epoxypropane 
• 600135-82-8 (3S,4R)-3-(3,4-dibenzyloxyphenoxymethyl)-4-(4-fluorophenyl)-1-methylpiperidine 
• 27688-85-3 3,4-Dibenzyloxyphenyl-acetat 
• 851279-13-5 1,2-di-O-benzyl-4-O-diethylcarbamoylbenzenetriol 
• 1023277-69-1 trifluoromethanesulfonic acid 3,4-bis(benzyloxy)phenyl ester 
• 916754-88-6 1,2-Bis-benzyloxy-4-(3,3-dimethoxy-propoxy)-benzene 
• 916754-90-0 6,7-bis-benzyloxy-2H-chromene 

Relevant articles and documents

NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME

The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins.

Hybridization of β-Adrenergic Agonists and Antagonists Confers G Protein Bias

Starting from the β-adrenoceptor agonist isoprenaline and beta-blocker carvedilol, we designed and synthesized three different chemotypes of agonist/antagonist hybrids. Investigations of ligand-mediated receptor activation using bioluminescence resonance energy transfer biosensors revealed a predominant effect of the aromatic head group on the intrinsic activity of our ligands, as ligands with a carvedilol head group were devoid of agonistic activity. Ligands composed of a catechol head group and an antagonist-like oxypropylene spacer possess significant intrinsic activity for the activation of Gαs, while they only show weak or even no β-arrestin-2 recruitment at both β1- and β2-AR. Molecular dynamics simulations suggest that the difference in G protein efficacy and β-arrestin recruitment of the hybrid (S)-22, the full agonist epinephrine, and the β2-selective, G protein-biased partial agonist salmeterol depends on specific hydrogen bonding between Ser5.46 and Asn6.55, and the aromatic head group of the ligands.

Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant

A series of A-ring-modified lamellarin N analogues were designed, synthesized, and evaluated as potential noncovalent inhibitors of the EGFR T790M/L858R mutant, a causal factor in the drug-resistant non-small cell lung cancer. Several water-soluble ammonium- or guanidinium-tethered analogues exhibited good kinase inhibitory activities. The most promising analogue, 14f, displayed an excellent inhibitory profile against the T790M/L858R mutant [IC50 (WT) = 31.8 nM; IC50 (T790M/L858R) = 8.9 nM]. The effects of A-ring-substituents on activity were rationalized by docking studies.